Patents by Inventor Pål Stenmark

Pål Stenmark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY
    Publication number: 20230110478
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 13, 2023
    Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
  • 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
    Patent number: 11504368
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: November 22, 2022
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Christoffer Bengtsson, Sanjay Borhade, Martin Haraldsson, Thomas Helleday, Martin Henriksson, Evert Homan, Cynthia Paulin, Lars Sandberg, Martin Scobie, Pål Stenmark, Karl Vallin
  • 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY
    Publication number: 20210052587
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Application
    Filed: April 17, 2019
    Publication date: February 25, 2021
    Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
  • Botulinum Neurotoxin Biohybrid
    Publication number: 20200407702
    Abstract: The present invention relates to a novel botulinum neurotoxin (BoNT) Heavy Chain Binding domain (HC/TAB) adapted to synergistically bind to a synaptotagmin (Syt) receptor, a synaptic associated vesicle 2 (SV2) receptor and a ganglioside (Gang) receptor, as well as polypeptides comprising said novel HC/TAB, vectors encoding said polypeptides, and uses thereof.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 31, 2020
    Inventors: Pål Stenmark, Geoffrey Masuyer